Blood Markers Identify Women at Risk for Postpartum Depression
By LabMedica International staff writers Posted on 11 Aug 2015 |
The interaction between oxytocin receptor DNA methylation and genotype has been investigated and whether it is associated with risk of postpartum depression in women without depression in pregnancy.
Postpartum depression (PPD) affects up to 19% of women, negatively impacting maternal and infant health and reductions in plasma oxytocin levels have been associated with PPD and heritability studies have established a genetic contribution.
A team of scientist led by those at the University of Virginia (Charlottesville, VA, USA) carried out a case-control study that included 269 cases with PPD and 276 controls matched on age group, parity, and presence or absence of depressive symptoms in pregnancy as assessed by the Edinburgh Postnatal Depression Scale. Blood was sampled in individuals during pregnancy, between seven and 41 weeks gestation, during normal antenatal care medical visits.
Epigenotyping was performed on DNA extracted from whole blood that was subject to bisulfite treatment. Bisulfite converted DNA was used as a template for polymerase chain reaction (PCR) using a Pyromark PCR kit (Qiagen; Valencia, CA, USA). Pyrosequencing was performed using a suitable primer on a Qiagen Pyromark Q24 using PyroMark Gold Q24 Reagents.
No genetic/epigenetic interactions were found to predict PPD in the total sample. However the scientist identified a significant three-way interaction between the oxytocin receptor OXTR rs53576 genotype, OXTR methylation, and depression in pregnancy in both unadjusted and adjusted models. The authors concluded that depression is especially detrimental in the first year after birth when the mother’s affect and sensitivity to her infant shapes the level of mother–infant emotional engagement, and subsequently impacts the child’s development. The identification of genetic and epigenetic susceptibility to depression in pregnancy may be one key element in a multidisciplinary approach to reduce the development of PPD and hence the adverse sequelae of depression.
C. Sue Carter, PhD, a coauthor of the study said, “The role of the oxytocin system in maternal behavior is well known in rodents. Our work emphasizes its importance in the human maternal condition and places the epigenetic regulation of the oxytocin receptor at the forefront.” The authors hope that the oxytocin receptor marker they have identified will be useful to clinicians in identifying women at risk for postpartum depression. The study was published on July 21, 2015, in the journal Frontiers in Genetics.
Related Links:
University of Virginia
Qiagen
Postpartum depression (PPD) affects up to 19% of women, negatively impacting maternal and infant health and reductions in plasma oxytocin levels have been associated with PPD and heritability studies have established a genetic contribution.
A team of scientist led by those at the University of Virginia (Charlottesville, VA, USA) carried out a case-control study that included 269 cases with PPD and 276 controls matched on age group, parity, and presence or absence of depressive symptoms in pregnancy as assessed by the Edinburgh Postnatal Depression Scale. Blood was sampled in individuals during pregnancy, between seven and 41 weeks gestation, during normal antenatal care medical visits.
Epigenotyping was performed on DNA extracted from whole blood that was subject to bisulfite treatment. Bisulfite converted DNA was used as a template for polymerase chain reaction (PCR) using a Pyromark PCR kit (Qiagen; Valencia, CA, USA). Pyrosequencing was performed using a suitable primer on a Qiagen Pyromark Q24 using PyroMark Gold Q24 Reagents.
No genetic/epigenetic interactions were found to predict PPD in the total sample. However the scientist identified a significant three-way interaction between the oxytocin receptor OXTR rs53576 genotype, OXTR methylation, and depression in pregnancy in both unadjusted and adjusted models. The authors concluded that depression is especially detrimental in the first year after birth when the mother’s affect and sensitivity to her infant shapes the level of mother–infant emotional engagement, and subsequently impacts the child’s development. The identification of genetic and epigenetic susceptibility to depression in pregnancy may be one key element in a multidisciplinary approach to reduce the development of PPD and hence the adverse sequelae of depression.
C. Sue Carter, PhD, a coauthor of the study said, “The role of the oxytocin system in maternal behavior is well known in rodents. Our work emphasizes its importance in the human maternal condition and places the epigenetic regulation of the oxytocin receptor at the forefront.” The authors hope that the oxytocin receptor marker they have identified will be useful to clinicians in identifying women at risk for postpartum depression. The study was published on July 21, 2015, in the journal Frontiers in Genetics.
Related Links:
University of Virginia
Qiagen
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans